Evidence map›Paper›PMID 35648381›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2022

A chloroacetamide derivative as a potent candidate for fusariosis treatment.

Gabriella da Rosa Monte Machado, Stefânia Neiva Lavorato, William Lopes, Marilene Henning Vainstein, Mário Lettieri Teixeira, Ricardo José Alves, Saulo Fernandes de Andrade, Alexandre Meneghello Fuentefria

Open access · greenAbstract read
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Gabriella da Rosa Monte MachadoGraduate Program in Agricultural Microbiology and Environment, Federal University of Rio Grande Do Sul, Sarmento Leite no 500 - Farroupilha, Porto Alegre, RS, 90050-170, Brazil. gabbirosam@gmail.com.
Stefânia Neiva LavoratoCenter for Biological and Health Sciences, Federal University of Oeste da Bahia, Rua da Prainha no 1326 Morada Nobre, Barreiras, BA, 47810-047, Brazil.
William LopesBiotechnology Center, Federal University of Rio Grande Do Sul, Bento Gonçalves no 9500 - Campus do Vale, Porto Alegre, RS, 91501-970, Brazil.
Marilene Henning VainsteinBiotechnology Center, Federal University of Rio Grande Do Sul, Bento Gonçalves no 9500 - Campus do Vale, Porto Alegre, RS, 91501-970, Brazil.
Mário Lettieri TeixeiraPharmacology Laboratory, Federal Catarinense Institute, Highway SC 283 - Fragosos, Campus Concórdia, Concórdia, SC, 89703-720, Brazil.
Ricardo José AlvesDepartment of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Presidente Antônio Carlos no 6627 - Campus Pampulha, Belo Horizonte, Belo Horizonte, MG, 31270-901, Brazil.
Saulo Fernandes de AndradeGraduate Program in Agricultural Microbiology and Environment, Federal University of Rio Grande Do Sul, Sarmento Leite no 500 - Farroupilha, Porto Alegre, RS, 90050-170, Brazil.
Alexandre Meneghello FuentefriaGraduate Program in Agricultural Microbiology and Environment, Federal University of Rio Grande Do Sul, Sarmento Leite no 500 - Farroupilha, Porto Alegre, RS, 90050-170, Brazil.
Universidade Federal do Rio Grande do Sul · BRInstituto Federal Catarinense · BRUniversidade Federal de Minas Gerais · BRUniversidade Federal do Oeste da Bahia · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fusariosis has presented a significant increase in their incidence in the last years. This epidemiological panorama probably is due to the increasing profile of refractory susceptibility of Fusarium spp. to available drugs, especially in immunocompromised individuals. Thus, the development of new compounds with effectiveness on these organisms is a necessity. This study evaluated the antifungal potential of a chloroacetamide derivative (4-BFCA) against resistant Fusarium strains. As a result, the compound was effective against all strains (MIC range 12.5-50 μg/mL). The time kill assay demonstrated that 4-BFCA presents a concentration-dependent fungicidal action. Although its action mechanism has not yet been elucidated, it was possible to observe its efficacy through damages and alterations provoked along the hyphae of Fusarium spp. 4-BFCA maintained a high survival rate of Tenebrio molitor larvae, suggesting that it does not cause acute systemic toxicity on this host at the concentration evaluated. In addition, 4-BFCA was 83.33% effective in combating a fungal infection in vivo on the chorioallantoid membrane of embryonated eggs. Our results are very promising and arouse interest to investigate the action of 4-BFCA on Fusarium strains since it acts as a possible candidate for the development of new therapies for the treatment of fusariosis.

Indexed as

FusariosisFusariumAcetamidesAntifungal AgentsHumansAcetamidesAntifungal AgentschloroacetamideAntifungal resistanceAntifungal therapyChloroacetamide derivativesFusarium

Identifiers

PMID35648381
PMCPMC9433475
OpenAlexW4281805116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.